- Zanubrutinib - BRUKINSA (USA)
- Zilovertamab Vedotin
- Zoledronat - ZOMETA® sowie Generika
According to the NCI website, zanubrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Check for active clinical trials using this agent.
According to the Company BeiGene website
BRUKINSA IS NOW APPROVED FOR ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
More Information in English:
Link to National Cancer Institute
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com
A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity.
Indikationen/Anwendungsmöglichkeiten von Zometa gemäss Compendium®:
- Zur Behandlung von Patienten mit Knochenmetastasen solider Tumoren und bei multiplem Myelom in Verbindung mit einer antineoplastischen Standardtherapie.
- Behandlung der malignen Hyperkalzämie (HCM), definiert als albuminkorrigiertes Serum-Kalzium (cCa) >12.0 mg/dl [3.0 mmol/l]
Link zur Fachinformation des Compendium®
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
selleckchem